(Q47594824)

4 February 2018

title

HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation (English)

1 reference

4 February 2018

author name string

N Chaturvedi

series ordinal

1

1 reference

4 February 2018

language of work or name

English

0 references

publication date

1 January 2000

1 reference

4 February 2018

published in

The Lancet

1 reference

4 February 2018

volume

355

1 reference

4 February 2018

issue

9200

1 reference

4 February 2018

page(s)

246-247

1 reference

4 February 2018

MRC trial of treatment of mild hypertension: principal results. Medical Research Council Working Party

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

Rationale and design for the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Research Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2890%2900006-3

7 January 2021

10.1016/S0140-6736(90)00006-3

Identifiers

DOI

1 reference

4 February 2018

1 reference

4 February 2018